Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham Pombiliti Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentMass General Brigham Health PlanPolicy N/A

    Pombiliti (cipaglucosidase alfa-atga) Continuation Therapy

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    MassHealth managed Medicaid prior authorization for Pombiliti administered through the medical benefit for adults with late-onset Pompe disease who meet applicable clinical and treatment criteria.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyPombiliti (cipaglucosidase alfa-atga) Continuation Therapy
    Policy CodePolicy N/A
    Change TypeFormatting update
    Effective DateJanuary 4, 2027
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for Pombiliti through the medical benefit under the MassHealth UPPL program.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 yearMaximum approval duration
    ≥40 kgMinimum member weight
    ≥18 yearsMinimum member age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    90 daysNew-to-plan documentation period
    MassHealth UPPLApplicable plan program
    MedicalAuthorization benefit

    Authorization Requirements

    Authorization pathways

    Authorization may be granted through either of the following pathways:

    ONE authorization pathway

    • New-to-plan pathway

      • Member is new to the plan, as evidenced by a coverage effective date of less than or equal to 90 days.
      • Medical records document that the member is currently receiving treatment with the requested drug, excluding treatment obtained as samples or through a manufacturer's patient assistance program.
    • Alternative clinical criteria pathway

      • Diagnosis of late-onset Pompe disease.
      • Prescriber is a specialist in genetic or metabolic diseases, or consult notes from a specialist are provided.
      • Member's current weight is ≥ 40 kg.
      • ONE diagnostic test confirming diagnosis

        • GAA assay test results show reduced or absent activity from cultured skin fibroblasts.
        • Lymphocyte testing supports the diagnosis.
        • Blood spot assay supports the diagnosis.
        • Genetic testing confirms a mutation in the GAA gene.
      • Member is ≥18 years of age.
      • ONE treatment-related criterion

        • Inadequate response or adverse reaction to ONE therapy

          • Inadequate response or adverse reaction to Lumizyme.
          • Inadequate response or adverse reaction to Nexviazyme.
        • Contraindication to BOTH therapies

          • Contraindication to Lumizyme.
          • Contraindication to Nexviazyme.
      • Requested agent will be used in combination with Opfolda (miglustat 65 mg).
      • Dosing is appropriate within FDA labeling.

    New-to-plan documentation requirement

    • For a member new to the plan, the coverage effective date is less than or equal to 90 days.
    • Medical records document current treatment with the requested drug; treatment obtained as samples or through a manufacturer's patient assistance program does not document current treatment.

    For members new to the plan, as evidenced by a coverage effective date of less than or equal to 90 days, medical records must document that the member is currently receiving treatment with the requested drug. Treatment obtained as samples or through a manufacturer's patient assistance program does not document current treatment.

    Lumizyme or Nexviazyme should not be used concurrently with Opfolda and Pombiliti.

    Continuing Coverage

    Continuation Therapy Response

    For continuation therapy, resubmission by the prescriber will infer a positive response to therapy.

    Continuation therapy resubmission: A prescriber resubmission is treated as indicating a positive response to Pombiliti therapy.

    Required Prior Therapy

    StepPrior therapy requirementRequirement before Pombiliti
    1Lumizyme or NexviazymeMember must have an inadequate response or adverse reaction to one of these agents, or a contraindication to both agents.

    Prior Authorization and Documentation

    Prior Authorization

    Medical-Benefit Prior Authorization Required

    Prior authorization is required through the medical benefit for Pombiliti under the MassHealth UPPL. Submit requests to the medical-benefit prior authorization channel.

    • Medical Benefit phone: 833-895-2611
    • Medical Benefit fax: 888-656-6671
    Step Therapy

    Required Prior Enzyme-Replacement Therapy

    Document inadequate response or an adverse reaction to one prior enzyme-replacement therapy, or a contraindication to both therapies.

    • Lumizyme
    • Nexviazyme
    • Lumizyme or Nexviazyme must not be used concurrently with Opfolda and Pombiliti.

    Therapy Overview

    Pombiliti is indicated in combination with Opfolda for adults with late-onset Pompe disease caused by deficiency of lysosomal acid alphaglucosidase (GAA). The policy applies to members weighing at least 40 kg who are not improving on their current enzyme-replacement therapy.

    Key Terms

    Pompe disease
    ConditionA lysosomal storage disorder caused by deficiency of lysosomal acid alphaglucosidase, also called GAA.
    Late-onset Pompe disease
    DefinitionPompe disease presenting in adulthood.
    Policy age requirementMember must be at least 18 years of age.
    GAA
    Full nameLysosomal acid alphaglucosidase.
    Role in Pompe diseaseDeficiency of GAA causes Pompe disease.
    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyPombiliti (cipaglucosidase alfa-atga) Continuation Therapy
    Policy CodePolicy N/A
    Change TypeFormatting update
    Effective DateJanuary 4, 2027
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for Pombiliti through the medical benefit under the MassHealth UPPL program.
    SourceLink
    On This Page
    Authorization RequirementsContinuing CoverageRequired Prior TherapyPrior Authorization and DocumentationTherapy OverviewKey Terms
    Documentation Required

    Submit Current-Treatment Records

    For members new to the plan, submit medical records showing the member is currently receiving the requested drug. Current-treatment evidence is required when the coverage effective date is less than or equal to 90 days before the request.

    • Do not use product samples or manufacturer patient-assistance programs as proof of current treatment.
    Documentation Required

    Clinical Qualification Documentation

    Include records supporting every clinical qualification for authorization of Pombiliti.

    • Diagnosis of late-onset Pompe disease.
    • Prescriber is a specialist in genetic or metabolic diseases, or provide specialist consultation notes.
    • Current member weight is ≥ 40 kg and age is ≥ 18 years.
    • Diagnostic confirmation by reduced or absent GAA activity from cultured skin fibroblasts, lymphocyte testing, blood spot assay, or genetic testing confirming a mutation in the GAA gene.
    Denial Risk

    Insufficient Current-Treatment Documentation

    Requests for members new to the plan may be denied when required current-treatment records are not submitted within the applicable 90-day new-to-plan period. Records must demonstrate active treatment with the requested drug and cannot rely on samples or manufacturer assistance.

    • Applies when the coverage effective date is less than or equal to 90 days.
    • Submit medical records documenting current treatment with Pombiliti.
    Denial Risk

    Noncompliant Combination or Dosing

    Authorization may be denied if the requested agent is not used in the required combination or if dosing does not follow FDA labeling.

    • Pombiliti must be used in combination with Opfolda (miglustat 65 mg).
    • Dosing must be appropriate within FDA labeling.
    • Lumizyme or Nexviazyme must not be used concurrently with Opfolda and Pombiliti.